Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

Arthritis and Rheumatism

Volumn 48, Issue 1, 2003, Pages 35-45

  Weinblatt, Michael E ^b   Keystone, Edward C ^a   Furst, Daniel E ^b   Moreland, Larry W ^b   Weisman, Michael H ^b   Birbara, Charles A ^b   Teoh, Leah A ^b   Fischkoff, Steven A ^b   Chartash, Elliot K ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COLLAGENASES; COMBINED MODALITY THERAPY; ENZYME PRECURSORS; FATIGUE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; METALLOENDOPEPTIDASES; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037231533     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10697     Document Type: Article

References (25)

1. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum 1997;40:984-5.
2. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998;25:238-42.
3. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
4. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
5. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;138:695-706.
6. O'Dell J. Conventional DMARD options for patients with a suboptimal response to methotrexate. J Rheumatol Suppl 2001; 62:21-6.
7. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
8. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
9. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
10. Salfeld J, Kaymakçalan Z, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF antibody D2E7 [abstract]. Arthritis Rheum 1998;41 Suppl 9:S57.
11. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7. Ann Rheum Dis 1999;58 Suppl 1:170-2.
12. Kempeni J. Update on D2E7: a fully human anti-tumour necrosis factor α monoclonal antibody. Ann Rheum Dis 2000;59 Suppl 1:144-5.
13. Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB, et al. Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:660-9.
14. Den Broeder AA, Joosten LA, Saxne T, Heinegård D, Fenner H, Miltenburg AM, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002;61:311-8.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
17. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
18. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, Disability and Pain scales. J Rheumatol 1982;9:789-93.
19. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992;30:473-83.
20. Cella D, Webster K. Linking outcomes management to quality-of-life measurement. Oncology (Huntingt) 1997;11:232-35.
21. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
22. Nagase H, Suzuki K, Morodomi T, Enghild JJ, Salvesen G. Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix 1992;1 Suppl:237-44.
23. Cheung NT, Dawes PT, Poulton KV, Ollier WE, Taylor DJ, Mattey DL. High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. J Rheumatol 2000;27:882-7.
24. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16:313-20.
25. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46: 328-46.